Biotech · Public company · Cambridge, MA, US

Editas Medicine, Inc.

Ticker EDIT · SEC CIK 0001650664

Track this companyFree. Adds Editas Medicine, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials53 recruiting or active

Pipeline programs4From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline4

EDIT-101Phase 2 · Leber Congenital Amaurosis 10ClinicalTrials.gov · fetched Nov 12, 2026
EDIT-301Phase 2 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
EDIT-301Phase 2 · Transfusion Dependent Beta ThalassemiaClinicalTrials.gov · fetched Nov 12, 2026
Safety and efficacy assessmentsSickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026

A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301ENROLLING_BY_INVITATION · started Jun 17, 2024ClinicalTrials.gov NCT06363760 · fetched Nov 12, 2026
EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Apr 29, 2022ClinicalTrials.gov NCT05444894 · fetched Nov 12, 2026
A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started May 4, 2021ClinicalTrials.gov NCT04853576 · fetched Nov 12, 2026
Single Ascending Dose Study in Participants With LCA10PHASE1_PHASE2 · UNKNOWN · started Sep 26, 2019ClinicalTrials.gov NCT03872479 · fetched Nov 12, 2026
Natural History Study of CEP290-Related Retinal DegenerationCOMPLETED · started Dec 17, 2017ClinicalTrials.gov NCT03396042 · fetched Nov 12, 2026